-
公开(公告)号：US5278278A
公开(公告)日：1994-01-11
申请号：US020000
申请日：1993-02-17
申请人： Masaru Okamoto , Toshihide Inoue , Shiro Kataoka
发明人： Masaru Okamoto , Toshihide Inoue , Shiro Kataoka
IPC分类号： C08G63/60
CPC分类号： C08G63/605
摘要： The present invention relates to polyesters capable to give moldings having excellent flow characteristics, heat resistance and mechanical properties.These polyesters are prepared by copolymerizing specified amounts of specific dioxycompounds such as t-butylhydroquinone, phenylhydroquinone and so on with polyesters comprising specified amounts of p-hydroxybenzoic acid, 4,4'-dihydroxybiphenyl, hydroquinone and terephthalic acid or terephthalic acid and isophthalic acid.
摘要翻译： 本发明涉及能够赋予流动性，耐热性和机械特性优异的成型品的聚酯。 这些聚酯通过将指定量的特定二羟基化合物如叔丁基氢醌，苯基氢醌等与包含规定量的对羟基苯甲酸，4,4'-二羟基联苯，氢醌和对苯二甲酸或对苯二甲酸和间苯二甲酸的聚酯共聚来制备。
-
公开(公告)号：US08486402B2
公开(公告)日：2013-07-16
申请号：US13106280
申请日：2011-05-12
申请人： Tomoyuki Tahara , Yoshikatsu Kanai , Hitoshi Endou , Shiro Kataoka , Kazumasa Hasegawa , Tetsuya Yoshino
发明人： Tomoyuki Tahara , Yoshikatsu Kanai , Hitoshi Endou , Shiro Kataoka , Kazumasa Hasegawa , Tetsuya Yoshino
IPC分类号： A61K38/00
CPC分类号： C07K16/2896 , A61K2039/505 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.
摘要翻译： 公开了具有来自癌细胞的细胞膜的与CD98特异性结合能力并与具有氨基酸转运蛋白活性的蛋白质（例如LAT1）形成复合物的形式的人抗体或其功能片段。 该抗体以癌细胞表面的LAT1二聚体形式结合CD98，特异性地通过ADCC或CDC通过免疫系统侵袭表达CD98的癌细胞，并进一步通过LAT1抑制癌细胞的氨基酸摄取，抑制 癌细胞的生长。 因此，提供了作用于各种癌症的该抗体或其片段的癌症的预防和治疗剂，其对癌症是特异性的，并且不产生副作用。
-
公开(公告)号：US20070141054A1
公开(公告)日：2007-06-21
申请号：US11629779
申请日：2005-09-02
申请人： Shiro Kataoka , Takafumi Tomura , Noriko Otani
发明人： Shiro Kataoka , Takafumi Tomura , Noriko Otani
IPC分类号： A61K39/395 , C12N5/06
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2803 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/732 , C07K2317/734 , C07K2317/76
摘要： The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the immune system, and for which no HAHA is produced; and a preventive or therapeutic agent for various malignant tumors including solid tumors that are currently treated with difficulty, which contains the antibody or an antibody fragment thereof. Specifically, the antibody or a functional fragment thereof is capable of binding to A33 and is produced by a hybridoma M10 (accession No. FERM BP-10107), M96 (accession No. FERM BP-10108), M165 (accession No. FERM BP-10106), N26 (accession No. FERM BP-10109), Q47 (accession No. FERM BP-10104), Q54 (accession No. FERM BP-10105), or R5 (accession No. FERM BP-10107). The preventive or therapeutic agent for tumors contains the antibody or a functional fragment thereof.
摘要翻译： 本发明提供：可以结合A33的抗体或其抗体片段，其特异性地使用基于免疫系统的ADCC和CDC，并且不产生HAHA特异性攻击表达A33的肿瘤细胞; 以及包含抗体或其抗体片段的目前难以治疗的各种恶性肿瘤（包括实体瘤）的预防或治疗剂。 具体地，抗体或其功能片段能够结合A33，并且由杂交瘤M10（登录号FERM BP-10107），M96（登录号FERM BP-10108），M165（登录号FERM BP -10106），N26（登录号FERM BP-10109），Q47（登录号FERM BP-10104），Q54（登录号FERM BP-10105）或R5（登录号FERM BP-10107）。 肿瘤的预防或治疗剂含有抗体或其功能片段。
-
公开(公告)号：US07943745B2
公开(公告)日：2011-05-17
申请号：US12295991
申请日：2007-04-05
申请人： Tomoyuki Tahara , Yoshikatsu Kanai , Hitoshi Endou , Shiro Kataoka , Kazumasa Hasegawa , Tetsuya Yoshino
发明人： Tomoyuki Tahara , Yoshikatsu Kanai , Hitoshi Endou , Shiro Kataoka , Kazumasa Hasegawa , Tetsuya Yoshino
CPC分类号： C07K16/2896 , A61K2039/505 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.
摘要翻译： 公开了具有来自癌细胞的细胞膜的与CD98特异性结合能力并与具有氨基酸转运蛋白活性的蛋白质（例如LAT1）形成复合物的形式的人抗体或其功能片段。 该抗体以癌细胞表面的LAT1二聚体形式结合CD98，特异性地通过ADCC或CDC通过免疫系统侵袭表达CD98的癌细胞，并进一步通过LAT1抑制癌细胞的氨基酸摄取，抑制 癌细胞的生长。 因此，提供了作用于各种癌症的该抗体或其片段的癌症的预防和治疗剂，其对癌症是特异性的，并且不产生副作用。
-
公开(公告)号：US20070020271A1
公开(公告)日：2007-01-25
申请号：US10548054
申请日：2004-03-04
IPC分类号： A61K39/395 , A01K67/027
CPC分类号： C07K16/30 , A01K2217/05 , A01K2227/105 , A01K2267/0331 , A01K2267/0375 , A61K48/00 , A61K2039/505 , C07K16/2851 , C07K2317/21 , C07K2317/73
摘要： Methods and composition provided herein relate to the inhibition of proliferation, migration, and tubule formation of cells and are thus useful in treating angiogenesis associated diseases, including cancer, polycystic kidney disease, diabetic retinopathy, rheumatoid arthritis, and psoriasis. Disclosed are methods of inhibiting endothelial cell proliferation, migration, and tubule formation by administering an antibody specific for Tumor EndothPelial Markers (TEMs). Also disclosed are methods of inhibiting angiogenesis and tumor growth by administering a TEM-specific antibody and antibody compositions useful in such methods.
摘要翻译： 本文提供的方法和组合物涉及细胞的增殖，迁移和小管形成的抑制，因此可用于治疗血管生成相关疾病，包括癌症，多囊肾病，糖尿病性视网膜病，类风湿性关节炎和牛皮癣。 公开了通过施用针对肿瘤内侧标记（TEM）特异的抗体来抑制内皮细胞增殖，迁移和小管形成的方法。 还公开了通过施用在这些方法中有用的TEM特异性抗体和抗体组合物来抑制血管发生和肿瘤生长的方法。
-
公开(公告)号：US07115717B2
公开(公告)日：2006-10-03
申请号：US10478056
申请日：2002-05-17
申请人： Eiji Mori , Shiro Kataoka
发明人： Eiji Mori , Shiro Kataoka
IPC分类号： A61K39/395 , C07K16/30
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/73
摘要： Anti-TRAIL-R1 and R2 antibodies or functional fragments thereof, having at least one property selected from the following (a) to (c) of:(a) having activity to induce apoptosis in carcinoma cells expressing TRAIL-R1 and/or TRAIL-R2;(b) not having effect on normal human cells expressing TRAIL-R1 and/or TRAIL-R2; and(c) not inducing human hepatocyte toxicity.
摘要翻译： 具有选自以下（a）至（c）中的至少一种性质的抗TRAIL-R1和R2抗体或其功能片段：（a）具有诱导表达TRAIL-R1和/或TRAIL的癌细胞凋亡的活性 -R2; （b）对表达TRAIL-R1和/或TRAIL-R2的正常人细胞无作用; 和（c）不诱导人肝细胞毒性。
-
公开(公告)号：US20050249729A1
公开(公告)日：2005-11-10
申请号：US10721763
申请日：2003-11-26
申请人： Eiji Mori , Kazuhiro Motoki , Shiro Kataoka
发明人： Eiji Mori , Kazuhiro Motoki , Shiro Kataoka
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/73
摘要： Anti-TRAIL-R1 and R2 antibodies or functional fragments thereof, having at least one property selected from the following (a) to (c) of: (a) having activity to induce apoptosis in carcinoma cells expressing TRAIL-R1 and/or TRAIL-R2; (b) not having effect on normal human cells expressing TRAIL-R1 and/or TRAIL-R2; and (c) not inducing human hepatocyte toxicity, and an anti-TRAIL-R1 and R2 antibodies or functional fragments thereof, having the following properties: having activity to induce apoptosis in carcinoma cells independently of exogenous factors and as a monomer of an antibody.
摘要翻译： 具有选自以下（a）至（c）中的至少一种性质的抗TRAIL-R1和R2抗体或其功能片段：（a）具有诱导表达TRAIL-R1和/或TRAIL的癌细胞凋亡的活性 -R2; （b）对表达TRAIL-R1和/或TRAIL-R2的正常人细胞无作用; 和（c）不诱导人肝细胞毒性，以及具有以下性质的抗TRAIL-R1和R2抗体或其功能片段：具有独立于外源因子诱导癌细胞凋亡的活性和作为抗体单体的活性。
-
公开(公告)号：US08999329B2
公开(公告)日：2015-04-07
申请号：US13543183
申请日：2012-07-06
IPC分类号： A61K39/395 , C07K16/28 , C07K14/52 , C07K14/715 , A61K39/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K14/524 , C07K14/715 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/72 , C07K2317/74 , Y10S424/801 , Y10S424/809
摘要： This invention provides an agonist antibody to a human thrombopoietin receptor (human c-Mpl), and pharmaceutical compositions comprising the same for use in treatment of thrombocytopenia. The disclosed agonist antibody comprises (1) antibody constant regions comprising heavy and light chain constant regions, each of which may optionally contain domain substitutions, or may contain deletions, substitutions, additions, or insertions of amino acid residues, and (2) antibody variable regions capable of binding to and activating a human thrombopoietin receptor. The-agonist antibody further induces colony formation at a concentration of 10,000 ng/ml or lower, and has a maximal activity at least 50% higher than that of PEG-rHuMGDF and an 50% effective concentration (EC50) of 100 nM or less.
摘要翻译： 本发明提供了对人类血小板生成素受体（人c-Mpl）的激动剂抗体，以及包含其用于治疗血小板减少症的药物组合物。 所公开的激动剂抗体包含（1）包含重链和轻链恒定区的抗体恒定区，每个区可任选地含有结构域取代，或可含有氨基酸残基的缺失，替换，添加或插入，和（2）抗体可变 能够结合并激活人血小板生成素受体的区域。 激动剂抗体进一步诱导浓度为10,000ng / ml或更低的集落形成，并且具有比PEG-rHuMGDF高至少50％的最大活性和100nM或更低的50％有效浓度（EC 50）。
-
公开(公告)号：US08236314B2
公开(公告)日：2012-08-07
申请号：US13232277
申请日：2011-09-14
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , A61K2039/505 , C07K14/524 , C07K14/715 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/72 , C07K2317/74 , Y10S424/801 , Y10S424/809
摘要： This invention provides an agonist antibody to a human thrombopoietin receptor (human c-Mpl), and pharmaceutical compositions comprising the same for use in treatment of thrombocytopenia. The disclosed agonist antibody comprises (1) antibody constant regions comprising heavy and light chain constant regions, each of which may optionally contain domain substitutions, or may contain deletions, substitutions, additions, or insertions of amino acid residues, and (2) antibody variable regions capable of binding to and activating a human thrombopoietin receptor. The-agonist antibody further induces colony formation at a concentration of 10,000 ng/ml or lower, and has a maximal activity at least 50% higher than that of PEG-rHuMGDF and an 50% effective concentration (EC50) of 100 nM or less.
摘要翻译： 本发明提供了对人类血小板生成素受体（人c-Mpl）的激动剂抗体，以及包含其用于治疗血小板减少症的药物组合物。 所公开的激动剂抗体包含（1）包含重链和轻链恒定区的抗体恒定区，每个区可任选地含有结构域取代，或可含有氨基酸残基的缺失，替换，添加或插入，和（2）抗体可变 能够结合并激活人血小板生成素受体的区域。 激动剂抗体进一步诱导浓度为10,000ng / ml或更低的集落形成，并且具有比PEG-rHuMGDF高至少50％的最大活性和100nM或更低的50％有效浓度（EC 50）。
-
公开(公告)号：US20120053326A1
公开(公告)日：2012-03-01
申请号：US13232277
申请日：2011-09-14
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , A61K2039/505 , C07K14/524 , C07K14/715 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/72 , C07K2317/74 , Y10S424/801 , Y10S424/809
摘要： This invention provides an agonist antibody to a human thrombopoietin receptor (human c-Mpl), and pharmaceutical compositions comprising the same for use in treatment of thrombocytopenia. The disclosed agonist antibody comprises (1) antibody constant regions comprising heavy and light chain constant regions, each of which may optionally contain domain substitutions, or may contain deletions, substitutions, additions, or insertions of amino acid residues, and (2) antibody variable regions capable of binding to and activating a human thrombopoietin receptor. The-agonist antibody further induces colony formation at a concentration of 10,000 ng/ml or lower, and has a maximal activity at least 50% higher than that of PEG-rHuMGDF and an 50% effective concentration (EC50) of 100 nM or less.
摘要翻译： 本发明提供了对人类血小板生成素受体（人c-Mpl）的激动剂抗体，以及包含其用于治疗血小板减少症的药物组合物。 所公开的激动剂抗体包含（1）包含重链和轻链恒定区的抗体恒定区，每个区可任选地含有结构域取代，或可含有氨基酸残基的缺失，替换，添加或插入，和（2）抗体可变 能够结合并激活人血小板生成素受体的区域。 激动剂抗体进一步诱导浓度为10,000ng / ml或更低的集落形成，并且具有比PEG-rHuMGDF高至少50％的最大活性和100nM或更低的50％有效浓度（EC 50）。
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.032 秒)
